查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1526338

全球生物可吸收支架市場

Bioresorbable Stents
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 125 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

預計2030年全球生物可吸收支架市場將達12億美元

2023年全球生物可吸收支架市場估計為5.544億美元，預計到2030年將達到12億美元，2023-2030年分析期間複合年成長率為12.1%。聚合物生物可吸收支架是本報告分析的細分市場之一，預計複合年成長率為 12.8%，到分析期結束時將達到 9.052 億美元。分析期間，金屬基生物可吸收支架細分市場的複合年成長率預計為 10.2%。

全球生物可吸收支架市場趨勢及促進因素總結

生物可吸收支架，也稱為生物可吸收血管支架（BVS），代表了介入性心臟病學的重要進步。這些支架旨在手術後暫時支撐動脈，並隨著時間的推移逐漸溶解，留下天然血管。與永久留在體內的傳統金屬支架不同，生物可吸收支架由聚乳酸（PLA）等材料製成，可自然分解並被人體吸收。這種暫時性降低了與永久植入相關的長期風險，例如慢性發炎和晚期血栓症。臨床試驗表明，生物可吸收支架可有效治療冠狀動脈疾病，其效果與金屬支架相當，並且隨著時間的推移恢復血管的自然功能和靈活性也有優勢。

廣泛的研究和創新推動了生物可吸收支架的發展。這些支架旨在在血管成形術後的關鍵癒合期間為動脈提供必要的機械支撐。隨著時間的推移，支架會逐漸劣化，從而降低長期併發症的風險。此外，生物可吸收支架通常會塗上抗增生藥物，以進一步防止血管再阻塞或動脈血管再阻塞。機械支撐和藥物輸送的雙重功能改善了患者的治療效果。此外，先進影像處理技術和精密工程的使用改善了這些支架的部署和功效，使其成為更廣泛的患者和臨床環境的可行選擇。

生物可吸收支架市場的成長受到多種因素的推動。首先，心血管疾病，特別是冠狀動脈疾病的盛行率在全世界不斷增加，需要有效和創新的治療方案。其次，患者和醫療保健提供者對微創手術的需求不斷成長，刺激了生物可吸收支架的採用。這些支架為傳統方法提供了一種有前景的替代方案，並且符合微創干預的趨勢。第三，生物材料和支架設計的技術進步提高了生物可吸收支架的性能和安全性，使其對臨床醫生更具吸引力。最後，患者對這些支架的認知和接受度不斷提高，再加上多個地區有利的報銷政策，正在進一步推動市場成長。這些因素共同支持生物可吸收支架在現代心血管治療範例中不斷擴大的作用。

受訪企業範例（25家知名企業）

  • Abbott Laboratories, Inc.
  • Boston Scientific Corporation
  • Biotronik SE & Co. KG
  • Eurocor GmbH
  • Biosensors International Group Ltd.
  • Elixir Medical Corporation
  • InSitu Technologies, Inc.
  • Kyoto Medical Planning Co., Ltd.
  • Medinol Ltd.
  • Lepu Medical Technology（Beijing）Co., Ltd.
  • Alvimedica Saglik Ekipmanlari Pazarlama Satis ve Dagitim AS
  • Meril Life Sciences Pvt., Ltd.
  • Arterial Remodeling Technologies SA
  • iVascular SLU
  • Endocor GmbH

目錄

第1章調查方法

第 2 章執行摘要

  • 市場概況
  • 世界市場概覽
  • 市場展望
  • 競賽
  • 主要企業
  • 市場趨勢和促進因素
  • 全球市場展望

第3章市場分析

  • 歐洲
  • 亞太地區
  • 世界其他地區

第4章 比賽

簡介目錄
Product Code: MCP10697

Global Bioresorbable Stents Market to Reach US$1.2 Billion by 2030

The global market for Bioresorbable Stents estimated at US$554.4 Million in the year 2023, is expected to reach US$1.2 Billion by 2030, growing at a CAGR of 12.1% over the analysis period 2023-2030. Polymer-based Bioresorbable Stents, one of the segments analyzed in the report, is expected to record a 12.8% CAGR and reach US$905.2 Million by the end of the analysis period. Growth in the Metal-based Bioresorbable Stents segment is estimated at 10.2% CAGR over the analysis period.

Global Bioresorbable Stents Market - Key Trends & Drivers Summarized

Bioresorbable stents, also known as bioresorbable vascular scaffolds (BVS), represent a significant advancement in interventional cardiology. These stents are designed to provide temporary support to the artery after a procedure, gradually dissolving over time and leaving behind a natural vessel. Unlike traditional metal stents, which remain permanently in the body, bioresorbable stents are composed of materials like polylactic acid (PLA) that naturally break down and are absorbed by the body. This temporary nature reduces the long-term risks associated with permanent implants, such as chronic inflammation and late-stage thrombosis. Clinical trials have demonstrated the efficacy of bioresorbable stents in treating coronary artery disease, showing comparable outcomes to metallic stents with the added benefit of restoring the vessel's natural function and flexibility over time.

The development of bioresorbable stents has been propelled by extensive research and technological innovations. These stents are engineered to provide the necessary mechanical support to the artery during the critical healing period post-angioplasty. Over time, the stent gradually degrades, reducing the risk of long-term complications. Additionally, bioresorbable stents are often coated with antiproliferative drugs to further prevent restenosis, or re-narrowing of the artery. This dual function of providing mechanical support and drug delivery enhances the therapeutic outcomes for patients. Furthermore, the use of advanced imaging techniques and precision engineering has improved the deployment and efficacy of these stents, making them a viable option for a broader range of patients and clinical scenarios.

The growth in the bioresorbable stents market is driven by several factors. Firstly, there is an increasing prevalence of cardiovascular diseases globally, particularly coronary artery disease, which necessitates effective and innovative treatment options. Secondly, the rising demand for minimally invasive procedures among patients and healthcare providers is fueling the adoption of bioresorbable stents. These stents offer a promising alternative to traditional methods, aligning with the trend towards less invasive interventions. Thirdly, technological advancements in biomaterials and stent design are enhancing the performance and safety profile of bioresorbable stents, making them more attractive to clinicians. Lastly, the growing awareness and acceptance of these stents among patients, coupled with favorable reimbursement policies in several regions, are further boosting market growth. The confluence of these factors underscores the expanding role of bioresorbable stents in modern cardiovascular treatment paradigms.

Select Competitors (Total 25 Featured) -

  • Abbott Laboratories, Inc.
  • Boston Scientific Corporation
  • Biotronik SE & Co. KG
  • Eurocor GmbH
  • Biosensors International Group Ltd.
  • Elixir Medical Corporation
  • InSitu Technologies, Inc.
  • Kyoto Medical Planning Co., Ltd.
  • Medinol Ltd.
  • Lepu Medical Technology (Beijing) Co., Ltd.
  • Alvimedica Saglik Ekipmanlari Pazarlama Satis ve Dagitim A.S.
  • Meril Life Sciences Pvt., Ltd.
  • Arterial Remodeling Technologies SA
  • iVascular S.L.U
  • Endocor GmbH

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Bioresorbable Stents - Global Key Competitors Percentage Market Share in 2024 (E)
    • Coronary Artery Disease (CAD) - A Perspective
    • Causes and Symptoms
    • Treatment Options for Coronary Artery Disease
    • Percutaneous Coronary Intervention (PCI)
    • Coronary Stenting
    • Types of Coronary Stents
    • Bare Metal Stents (BMS)
    • Drug Eluting Stents (DES)
    • Bioresorbable Scaffolds
    • Design and Composition of Bioresorbable Scaffolds
    • Different Types of Bioresorbable Scaffolds
    • Metallic Bioresorbable Scaffolds
    • Polymer Bioresorbable Scaffolds
    • Degradation Period of Select Bioabsorbable Materials
    • Challenges
    • Clinical Characteristics of Various Coronary Stents
    • Other Treatment Options for Coronary Heart Disease
    • Coronary Artery Bypass Grafting (CABG)
    • Minimally Invasive Direct Coronary Artery Bypass (MIDCAB)
    • TransMyocardial Laser Revascularization (TMR)
    • Peripheral Arterial Disease: Understanding the Stealthy Peril
    • Treatment for PAD
    • Stenting- A Treatment Option for PAD
    • BioResorbable Stents - A Prelude
    • Bioresorbable Vascular Scaffolds: Advantages and Challenges
    • Bioresorbable Stents - A Revolutionary Technology, Riddled with Controversies
    • Abbott Stops Sales of the Once Promising 'Absorb' Bioresorbable Stents due to Adverse Events
    • Impact of Abbott's Withdrawal of Absorb on the Bioresorbable Stent Industry
  • GLOBAL MARKET OVERVIEW
    • Global Bioresorbable Stents Set to Witness Growth in Future
    • Europe Dominates, Asia-Pacific Exhibits Fastest Growth
    • CAD Constitutes the Leading Application
    • Metallic Vs. Polymer-based Stents
    • Bioabsorbable Metallic Stents
    • Bioabsorbable Polymer Stents
    • Disappointing Results by Absorb to Increase Focus on Metallic Stents
    • Availability of Alternative Treatments - Hindrance to Market Growth
    • Market Challenges
  • MARKET OUTLOOK
    • Bioresorbable and Integrated Biosensor Technology to Redefine Future of Vascular Stents
    • The Future of BRS Technology
  • COMPETITION
    • Select Approved Bioresorbable Scaffolds
    • Select Bioresorbable Stents in Pipeline
    • Abbott Revives Bioresorbable Stent Clinical Trials to Evaluate New Esprit Scaffold
    • Recent Market Activity
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Polymeric Resorbable Scaffolds Hold a Major Market Share
    • The Absorb BRS program
    • Desaminotyrosine Polycarbonate-based BRS
    • The FANTOM program
    • Magnesium-based BRS
    • The Magmaris program
    • Iron-based BRS
    • Global Menace of Coronary Artery Disease (CAD) - A Major Growth Driver
    • Global Annual Medical Cost of CVD in the United States: 2015-2030
    • Fatalities by Heart Conditions - Estimated Percentage Breakdown for Cardiovascular Disease, Ischemic Heart Disease, Stroke, and Others
    • Ageing Demographics and Longer Life Expectancy Bolsters Market Growth
    • Global Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050
    • Elderly Population (65+ Years) as a % of Total Population by Developed, Less Developed and Least Developed Regions: 2019 & 2030
    • Rising Middle Class Population Aids Growth
    • Global Middle Class Population (in Millions) by Geographic Region: 2010, 2020P & 2030P
    • Rising Healthcare Expenditure: Opportunities in Store
    • World Healthcare Expenditure (In US$ Billion) for the Years 2017-2023
    • Healthcare Costs as a % of GDP by Country for the Years 2020 & 2023
    • Risk of CAD in Obesity Offers Prospects for Coronary Stenting
    • Obesity Prevalence Rate (%) in Select Countries for the Years 2019 and 2030P
    • Diabetics at Higher Risk of Heart Diseases
    • TABLE 15: Diabetes Prevalence Worldwide by Region: Number of Adults (20-79 Years) with Diabetes in 2015 and 2040
    • The Hypertension-Cholesterol Link to Drive Demand
    • Hypertension Prevalence (%) Worldwide by Region in Male and Females Aged 25+ Years
    • Metal Bioresorbable scaffolds Exhibit Improved Performance Compared to Polymer Stents
    • Metal Stents Vis-a-Vis Other Stents
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Bioresorbable Stents by Geographic Region - Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 2: World 7-Year Perspective for Bioresorbable Stents by Geographic Region - Percentage Breakdown of Value Sales for Europe, Asia-Pacific and Rest of World Markets for Years 2024 & 2030
    • TABLE 3: World Recent Past, Current & Future Analysis for Polymer-based by Geographic Region - Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 4: World 7-Year Perspective for Polymer-based by Geographic Region - Percentage Breakdown of Value Sales for Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Metal-based by Geographic Region - Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 6: World 7-Year Perspective for Metal-based by Geographic Region - Percentage Breakdown of Value Sales for Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Coronary Artery Disease/CAD by Geographic Region - Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 8: World 7-Year Perspective for Coronary Artery Disease/CAD by Geographic Region - Percentage Breakdown of Value Sales for Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 9: World Recent Past, Current & Future Analysis for Peripheral Artery Disease/PAD by Geographic Region - Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 10: World 7-Year Perspective for Peripheral Artery Disease/PAD by Geographic Region - Percentage Breakdown of Value Sales for Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 12: World 7-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Cardiovascular Centers by Geographic Region - Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 14: World 7-Year Perspective for Cardiovascular Centers by Geographic Region - Percentage Breakdown of Value Sales for Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 15: World Bioresorbable Stents Market Analysis of Annual Sales in US$ Thousand for Years 2020 through 2030

III. MARKET ANALYSIS

  • EUROPE
    • Bioresorbable Stents Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 16: Europe Recent Past, Current & Future Analysis for Bioresorbable Stents by Material - Polymer-based and Metal-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 17: Europe 7-Year Perspective for Bioresorbable Stents by Material - Percentage Breakdown of Value Sales for Polymer-based and Metal-based for the Years 2024 & 2030
    • TABLE 18: Europe Recent Past, Current & Future Analysis for Bioresorbable Stents by Application - Coronary Artery Disease/CAD and Peripheral Artery Disease/PAD - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 19: Europe 7-Year Perspective for Bioresorbable Stents by Application - Percentage Breakdown of Value Sales for Coronary Artery Disease/CAD and Peripheral Artery Disease/PAD for the Years 2024 & 2030
    • TABLE 20: Europe Recent Past, Current & Future Analysis for Bioresorbable Stents by End-Use - Hospitals and Cardiovascular Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 21: Europe 7-Year Perspective for Bioresorbable Stents by End-Use - Percentage Breakdown of Value Sales for Hospitals and Cardiovascular Centers for the Years 2024 & 2030
  • ASIA-PACIFIC
    • Bioresorbable Stents Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 22: Asia-Pacific Recent Past, Current & Future Analysis for Bioresorbable Stents by Material - Polymer-based and Metal-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 23: Asia-Pacific 7-Year Perspective for Bioresorbable Stents by Material - Percentage Breakdown of Value Sales for Polymer-based and Metal-based for the Years 2024 & 2030
    • TABLE 24: Asia-Pacific Recent Past, Current & Future Analysis for Bioresorbable Stents by Application - Coronary Artery Disease/CAD and Peripheral Artery Disease/PAD - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 25: Asia-Pacific 7-Year Perspective for Bioresorbable Stents by Application - Percentage Breakdown of Value Sales for Coronary Artery Disease/CAD and Peripheral Artery Disease/PAD for the Years 2024 & 2030
    • TABLE 26: Asia-Pacific Recent Past, Current & Future Analysis for Bioresorbable Stents by End-Use - Hospitals and Cardiovascular Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 27: Asia-Pacific 7-Year Perspective for Bioresorbable Stents by End-Use - Percentage Breakdown of Value Sales for Hospitals and Cardiovascular Centers for the Years 2024 & 2030
  • REST OF WORLD
    • TABLE 28: Rest of World Recent Past, Current & Future Analysis for Bioresorbable Stents by Material - Polymer-based and Metal-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 29: Rest of World 7-Year Perspective for Bioresorbable Stents by Material - Percentage Breakdown of Value Sales for Polymer-based and Metal-based for the Years 2024 & 2030
    • TABLE 30: Rest of World Recent Past, Current & Future Analysis for Bioresorbable Stents by Application - Coronary Artery Disease/CAD and Peripheral Artery Disease/PAD - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 31: Rest of World 7-Year Perspective for Bioresorbable Stents by Application - Percentage Breakdown of Value Sales for Coronary Artery Disease/CAD and Peripheral Artery Disease/PAD for the Years 2024 & 2030
    • TABLE 32: Rest of World Recent Past, Current & Future Analysis for Bioresorbable Stents by End-Use - Hospitals and Cardiovascular Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 33: Rest of World 7-Year Perspective for Bioresorbable Stents by End-Use - Percentage Breakdown of Value Sales for Hospitals and Cardiovascular Centers for the Years 2024 & 2030

IV. COMPETITION